U.S. Markets closed

Foundation Medicine, Inc. (FMI)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
38.65-0.05 (-0.13%)
At close: 4:00PM EDT
People also watch
BPMCEPZMCRCMGHDXAGIO
Full screen
Previous Close38.70
Open38.55
Bid35.20 x 100
Ask42.50 x 100
Day's Range38.35 - 38.90
52 Week Range17.10 - 43.15
Volume57,844
Avg. Volume165,939
Market Cap1.39B
Beta0.42
PE Ratio (TTM)-8.65
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cube10 days ago

    ETFs with exposure to Foundation Medicine, Inc. : September 13, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Foundation Medicine, Inc. Here are 5 ETFs with the largest exposure to FMI-US. Comparing the performance and risk of Foundation Medicine, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Foundation Medicine, Inc. :FMI-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017
    Capital Cube12 days ago

    Foundation Medicine, Inc. :FMI-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017

    Categories: Yahoo FinanceGet free summary analysis Foundation Medicine, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Foundation Medicine, Inc. – Veracyte Inc, Biocept, Inc., Genomic Health, Inc., Myriad Genetics, Inc., Trovagene, Inc., Illumina, Inc., Vermillion, Inc. and Laboratory Corporation of America Holdings (VCYT-US, BIOC-US, ... Read more (Read more...)

  • Reuters16 days ago

    Roche blood test could help 'personalise' cancer immunotherapy

    A new blood test from Roche and Foundation Medicine has shown it can accurately measure the number of mutations within a tumour, potentially helping to predict which patients may respond best to some immunotherapies. Initial data on Roche's test aimed at determining tumour mutational burden, or TMB, was released on Friday at the European Society for Medical Oncology (ESMO) congress in Madrid.